DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center

Similar documents
Venous Thromboembolism. Prevention

Misunderstandings of Venous thromboembolism prophylaxis

DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)

Mabel Labrada, MD Miami VA Medical Center

Objectives. Venous Thromboembolism (VTE) Prophylaxis. Case VTE WHY DO IT? Question: Who Is At Risk?

Venous Thromboembolism Prophylaxis: Checked!

VTE Management in Surgical Patients: Optimizing Prophylaxis Strategies

Prevention of Venous Thromboembolism

Prevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales

PE and DVT. Dr Anzo William Adiga WatsApp or Call Medical Officer/RHEMA MEDICAL GROUP

Slide 1. Slide 2. Slide 3. Outline of This Presentation

CADTH Rapid Response Report: ASA for Venous Thromboembolism Prophylaxis: Evidence for Clinical Benefit and Harm

Risk factors for DVT. Venous thrombosis & pulmonary embolism. Anticoagulation (cont d) Diagnosis 1/5/2018. Ahmed Mahmoud, MD

Venous thrombosis & pulmonary embolism. Ahmed Mahmoud, MD

Approach to Thrombosis

Medical Patients: A Population at Risk

CANCER ASSOCIATED THROMBOSIS. Pankaj Handa Department of General Medicine Tan Tock Seng Hospital

Anticoagulation for prevention of venous thromboembolism

Thrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI

Venous Thromboembolism Prophylaxis

EXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS

THROMBOTIC DISORDERS: The Final Frontier

10/8/2012. Disclosures. Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines. Goals and Objectives. Outline

Venous Thromboembolism Prophylaxis - Why Should We Care? Harry Gibbs FRACP FCSANZ Vascular Physician The Alfred Hospital

Measurement and Improvement of Quality of Cardiovascular Care DR : DEHESTANI

Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders

Primary VTE Prophylaxis. Ponlapat Rojnuckarin, MD PhD Chulalongkorn University Bangkok, Thailand

CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM. Gordon Lowe Professor of Vascular Medicine University of Glasgow

Thrombosis. By Dr. Sara Mohamed Abuelgasim

VTE in the Trauma Population

Fatal P.E. Historic 1-2% Current %

Early Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement. Marilyn Szekendi, PhD, RN

General. Recommendations. Guideline Title. Bibliographic Source(s) Guideline Status. Major Recommendations

Heparin-Induced Thrombocytopenia. Steven Baroletti, PharmD., M.B.A., BCPS Brigham and Women s Hospital

Venous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community

THROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY

10 Key Things the Vascular Community Should Know about the DOACs Heather Gornik, MD, RVT, RPVI

Updates in Diagnosis & Management of VTE

New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY

Tarkten A Pharr, MD, FACS 04/26/2018. VTE Prevention Strategies: Is a One Size Fits all Approach Correct?

Venous Thrombo-Embolism. John de Vos Consultant Haematologist RSCH

CHAPTER 2 VENOUS THROMBOEMBOLISM

Pulmonary Thromboembolism

Jessica Bryan, Natalia Evans, Karlyn Henderson, & Whitney Parks

Predicting Venous Thromboembolic Complications following Neurosurgical Procedures

New Oral Anticoagulant Drugs in the Prevention of DVT

Challenges in Anticoagulation and Thromboembolism

CMS National Patient Safety Initiative for Surgical Care

Prophylaxis for Hospitalized and Non-Hospitalized Medical Patients

NOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.

Disclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None

Updates in Management of Venous Thromboembolic Disease

DEEP VEIN THROMBOSIS (DVT): TREATMENT

Anticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita

INDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY

Inherited Thrombophilia Testing. George Rodgers, MD, PhD Kristi Smock MD

Perioperative Management of the Anticoagulated Patient

Aspirin as Venous Thromboprophylaxis

3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?

Menopausal Hormone Therapy & Haemostasis

ADVANCES IN ANTICOAGULATION

How long to continue anticoagulation after DVT?

What are blood clots?

Perioperative VTE prophylaxis (ACCP 9 th edition Guidelines) Gamal Marey SUNY Downstate Medical Center 10/16/2014

Prevention of VTE in Nonsurgical Patients

Cancer Associated Thrombosis An update.

The Need for Venous Thromboembolism (VTE) Prophylaxis in Plastic Surgery

What is the impact of Superficial Vein Thrombosis?

Hemostasis. PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures

THROMBOSIS RISK FACTOR ASSESSMENT

Dave Duddleston, MD VP and Medical Director Southern Farm Bureau Life

1. SCOPE of GUIDELINE:

4/23/2009. September 15, 2008

PROGNOSIS AND SURVIVAL

Venous Thromboembolism National Hospital Inpatient Quality Measures

Cancer and the Heparins

4/30/2018 CLOT+ In patients with an acute proximal deep vein thrombosis, pharmacomechanical catheter-directed thrombolysis does not reduce t

Factor Xa Inhibition in the Management of Venous Thromboembolism: Important Safety Information. Important Safety Information (cont d)

Primary VTE Thromboprophylaxis

Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism

Genetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수

10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy:

Symptomatic Venous Thromboembolism after Total Hip/Knee Replacement: A Population-based Taiwan Study

New oral anticoagulants and Palliative Care.

Epidemiology of Thrombosis in Patients with Malignancy. Cancer and Venous Thromboembolism. Chew HK, Arch Int Med, Feb Blom et al, JAMA, Feb 2005

Obesity, renal failure, HIT: which anticoagulant to use?

Cancer and Thrombosis

Pulmonary Embolectomy:

Icd 10 thromboembolic pulmonary hypertension

PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM

VTE ACHIEVEMENTS AND CHALLENGES: 2012 AND BEYOND Samuel Z. Goldhaber, MD Director, VTE Research Group Cardiovascular Division Brigham and Women s

Deep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H

Post-Traumatic Thromboembolism. Pathogenesis, Diagnosis and Prevention M. Margaret Knudson, MD

DOACs in CAT. Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD

How to prevent thrombotic diseases? Sergio Fusco, MD

Getting Started Kit VENOUS THROMBOEMBOLISM PREVENTION. Section 2: Evidence-Based Appropriate VTE Prophylaxis

Objectives. Heparin. Heparin & HIT: State of the Art. Acknowledge Heparin (almighty) HIT? Why care? Is it HIT? It is HIT. Now what?

Thrombophilia: To test or not to test

Do s and Don t of DOACs DISCLOSURE

Transcription:

DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients David Liff MD Oklahoma Heart Institute Vascular Center

Overview Pathophysiology of DVT Epidemiology and risk factors for DVT in the community DVT prophylaxis in the acutely ill, hospitalized patient

Tis but a Scratch

Virchow s Triad Vessel wall changes Blood stasis Hypercoagulability

Clot Formation in the Artery 1. Vessel wall damage (plaque rupture, trauma) 2. Platelets bind the damaged endothelium 3. Thrombin binds platelets and fibrin clot forms

Arterial vs. Venous Thrombus Nature 2008;451(7181):914

Coagulation Cascade 1. How does Tissue Factor get to the vein? Tissue Factor 2. Why does Tissue Factor adhere to the intact endothelium? Thrombin and Fibrin

How Does Tissue Factor get into the Blood? Cancer TF-MV Pregnancy TF-MV Leukocytes TF-MV Inflammation TF-MV TF-MV Sepsis

Why Does Tissue Factor Adhere to the Vein? Ann Royal Coll Surg 1984;66:416 Arterioscler Thromb Vasc Biol 2012;32:563

Venous Thrombosis Tissue factor-microvesicles TF+VIIa Xa + Va fx Prothrombin Leukocyte Thrombin Fibrinogen Fibrin Red cells, Platelets

Valve Cusp Thrombus J Clin Path 1972;27:517-528

Hypercoagulable Conditions Genetic Increased coagulants Prothrombin mutation: 8% Decreased anticoagulants AT deficiency: 1% Protein C: 2-5% Protein S: 2% Factor V Leiden: 20-25% Acquired Malignancy Hyperhomocysteinemia OCT s Pregnancy Nephrotic syndrome Antiphospholipid antibodies Chest 2002;1222:1440-1456

DVT Epidemiology 548,000 annual admissions for VTE Contributes to 100,000 deaths annually in the US Accounts for up to 15% of unexpected hospital deaths Costs > $10 billion annually Nat Rev Cardiol 2015;12(8):464 J. Hosp. Med 2012;9;706-708

Who Gets VTE in the Community? 45% 13% 24% 18% Surgery or hospitalization Nursing home Cancer Idiopathic Arch Inter Med 2002;162:1245

VTE Risk Factors OR for DVT 20 18 16 14 12 10 8 6 4 2 0 Nat Rev Cardiol 2015;12(8):464

DVT in the Hospital Medical Admission Surgical Population Pelvic Fracture 0.08% 30% 60% Lancet 2005;365:1163

DVT Prevention Pharmacoprophylaxis Heparin LMWH Dabigatran/Argatroban Apixiban/Rivaroxaban Mechanical Prophylaxis Graduated compression stockings Intermittent pneumatic compression devices (ICP) Venous foot pumps

Any Anticoagulant vs. None to Prevent VTE Nearly 50% reduction in Symptomatic DVT in all orthopedic surgery patients Chest 2012;141(2):e278s

Decision Algorithm DVT risk? Bleed risk? Pharmacoprophylaxis Prophylaxis High Intermittent pneumatic compression Or Graduated compression stockings Low Intermittent pneumatic compression Or Graduated compression stockings

Padua Study-who is high risk? Padua Prediction Score-derived from a prospective observational study of all medical admission to a hospital. All patients without a need for anticoagulation were characterized prospectively as high or low risk based on a risk prediction model. Patients were followed for 3 months Primary outcome was symptomatic VTE within 3 months of hospitalization J Thromb Haemost 2010;8:2450

High vs. Low Risk? 60 50 1540 10 30 20 510 0 0 VTE Rate Low Risk Prophylaxis No prophylaxis High risk is > 4 High risk low risk J Thromb Haemost 2010;8:2450

CHEST Physicians: Anticipated Absolute Effect Events/1 1,000 pts 40 30 20 10 0 Overall mortality 0.1%!!! Symptom atic DVT Non-fatal PE Fatal PE High Risk 34 15 2 1 Low Risk 1 1 0 1 Major Bleeding Chest 2012;141(2):e195s

CHEST Guidelines For hospitalized patients at increased risk of thrombosis, anticoagulation is recommended (IB) For hospitalized patients at low risk of thrombosis, we recommend against the use of anticoagulation (IB) For acutely ill hospitalized medical patients at increased risk of thrombosis, we recommend anticoagulant thromboprophylaxis with LMWH, low dose unfractionated heparin BID or TID, or fondaparinux (IB) Chest 2012;141(2):e195s

What About People who are Bleeding? Bleeding occurs in < 1% of patients due to prophylaxis 10% of acutely ill hospitalized patients are at high risk for bleeding Over half of all bleeds occur in patients at high risk for bleeding Active GI ulcer Bleeding w/in 3 mos Plt < 50 Age > 85 Hepatic failure (INR > 1.5) Renal failure (GFR <30) ICU or CCU admission Central venous catheter Rheumatic disease Active cancer male Odds Ratio for bleeding 0 1 2 3 4 5 Chest 2012;141(2):e195s

Graduated Compression Stockings /1000 patients Events prevented/ 16 14 12 10 8 6 4 2 High risk Low risk 0 Symptomatic DVT Non-fatal PE Chest 2012;141(2):e195s

Intermittent Pneumatic Compression Used in 22% of US patients vs. 0.2% in other countries Not studied in medical admission patients No proven reduction in PE or mortality Does prevent symptomatic DVT in surgical patients (RR 0.43) Chest 2012;141(2):e195s

CHEST Guidelines For patients at high risk of bleeding or actively bleeding, don t use anticoagulation prophylaxis (IB) For patients at high risk of bleeding or actively bleeding, optimal use of graduated compression stockings or intermittent pneumatic compression is recommended (IIC) Weigh risks and benefits in patients at risk for skin complications

Decision Algorithm DVT risk? Bleed risk? Pharmacoprophylaxis Prophylaxis High Intermittent pneumatic compression Or Graduated compression stockings Low Intermittent pneumatic compression Or Graduated compression stockings